These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 33563323)

  • 1. Characteristics of BRCA1/2 pathogenic germline mutations in chinese NSCLC patients and a comparison with HBOC.
    Xu Z; Wang Y; Wang L; Cui F; Zhang L; Xiong J; Peng H
    Hered Cancer Clin Pract; 2021 Feb; 19(1):16. PubMed ID: 33563323
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Comparison of hereditary breast and ovarian cancer syndrome and sporadic ovarian cancer in ovarian cancer BRCA mutations].
    Duan RR; Sun LX; Zhao HW
    Zhonghua Fu Chan Ke Za Zhi; 2021 Nov; 56(11):788-795. PubMed ID: 34823292
    [No Abstract]   [Full Text] [Related]  

  • 3. A novel germline BRCA1 mutation identified in a family with hereditary breast and ovarian cancer syndrome.
    Wu Y; Pan X; Dou J; Zhang Q; Li Y; Sheng Y; Liu X
    Clin Med Insights Oncol; 2021; 15():11795549211028569. PubMed ID: 34276234
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The frequency of cancer predisposition gene mutations in hereditary breast and ovarian cancer patients in Taiwan: From BRCA1/2 to multi-gene panels.
    Sung PL; Wen KC; Chen YJ; Chao TC; Tsai YF; Tseng LM; Qiu JT; Chao KC; Wu HH; Chuang CM; Wang PH; Huang CF
    PLoS One; 2017; 12(9):e0185615. PubMed ID: 28961279
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Histology of prophylactically removed ovaries from BRCA1 and BRCA2 mutation carriers compared with noncarriers in hereditary breast ovarian cancer syndrome kindreds.
    Casey MJ; Bewtra C; Hoehne LL; Tatpati AD; Lynch HT; Watson P
    Gynecol Oncol; 2000 Sep; 78(3 Pt 1):278-87. PubMed ID: 10985881
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prevalence of BRCA1/BRCA2 mutations in a Brazilian population sample at-risk for hereditary breast cancer and characterization of its genetic ancestry.
    Fernandes GC; Michelli RA; Galvão HC; Paula AE; Pereira R; Andrade CE; Felicio PS; Souza CP; Mendes DR; Volc S; Berardinelli GN; Grasel RS; Sabato CS; Viana DV; Mauad EC; Scapulatempo-Neto C; Arun B; Reis RM; Palmero EI
    Oncotarget; 2016 Dec; 7(49):80465-80481. PubMed ID: 27741520
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Peritoneal carcinoma in women with genetic susceptibility: implications for Jewish populations.
    Casey MJ; Bewtra C
    Fam Cancer; 2004; 3(3-4):265-81. PubMed ID: 15516851
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intra-abdominal carcinomatosis after prophylactic oophorectomy in women of hereditary breast ovarian cancer syndrome kindreds associated with BRCA1 and BRCA2 mutations.
    Casey MJ; Synder C; Bewtra C; Narod SA; Watson P; Lynch HT
    Gynecol Oncol; 2005 May; 97(2):457-67. PubMed ID: 15863145
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prevalence and clinical significance of pathogenic germline
    Hu X; Yang D; Li Y; Li L; Wang Y; Chen P; Xu S; Pu X; Zhu W; Deng P; Ye J; Zhang H; Lizaso A; Liu H; Mao X; Huang H; Chu Q; Hu C
    Cancer Biol Med; 2019 Aug; 16(3):556-564. PubMed ID: 31565484
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Genetic and clinical characterization of BRCA-associated hereditary breast and ovarian cancer in Navarra (Spain).
    Ruiz de Sabando A; Urrutia Lafuente E; García-Amigot F; Alonso Sánchez A; Morales Garofalo L; Moreno S; Ardanaz E; Ramos-Arroyo MA
    BMC Cancer; 2019 Nov; 19(1):1145. PubMed ID: 31771539
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Frequency of BRCA1 and BRCA2 germline mutations in Japanese breast cancer families.
    Ikeda N; Miyoshi Y; Yoneda K; Shiba E; Sekihara Y; Kinoshita M; Noguchi S
    Int J Cancer; 2001 Jan; 91(1):83-8. PubMed ID: 11149425
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identification of germline pathogenic variants in DNA damage repair genes by a next-generation sequencing multigene panel in BRCAX patients.
    Rodríguez-Balada M; Roig B; Melé M; Albacar C; Serrano S; Salvat M; Querol M; Borràs J; Martorell L; Gumà J
    Clin Biochem; 2020 Feb; 76():17-23. PubMed ID: 31786208
    [TBL] [Abstract][Full Text] [Related]  

  • 13. BRCA1 and BRCA2 mutations in Danish families with hereditary breast and/or ovarian cancer.
    Thomassen M; Hansen TV; Borg A; Lianee HT; Wikman F; Pedersen IS; Bisgaard ML; Nielsen FC; Kruse TA; Gerdes AM
    Acta Oncol; 2008; 47(4):772-7. PubMed ID: 18465347
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Quantitative Analysis of
    Farber-Katz S; Hsuan V; Wu S; Landrith T; Vuong H; Xu D; Li B; Hoo J; Lam S; Nashed S; Toppmeyer D; Gray P; Haynes G; Lu HM; Elliott A; Tippin Davis B; Karam R
    Front Oncol; 2018; 8():286. PubMed ID: 30101128
    [TBL] [Abstract][Full Text] [Related]  

  • 15. OLA1 gene sequencing in patients with BRCA1/2 mutation-negative suspected hereditary breast and ovarian cancer.
    Takahashi M; Chiba N; Shimodaira H; Yoshino Y; Mori T; Sumii M; Nomizu T; Ishioka C
    Breast Cancer; 2017 Mar; 24(2):336-340. PubMed ID: 27271530
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Germline and Somatic
    You Y; Li L; Lu J; Wu H; Wang J; Gao J; Wu M; Liang Z
    Front Oncol; 2020; 10():295. PubMed ID: 32211327
    [No Abstract]   [Full Text] [Related]  

  • 17. Analysis of clinical characteristics of breast cancer patients with the Japanese founder mutation
    Yoshida R; Watanabe C; Yokoyama S; Inuzuka M; Yotsumoto J; Arai M; Nakamura S;
    Oncotarget; 2019 May; 10(35):3276-3284. PubMed ID: 31143373
    [No Abstract]   [Full Text] [Related]  

  • 18. [Current clinical issues and recent trends in hereditary breast and ovarian cancer in Japan-genetic testing for HBOC and risk-reducing surgery].
    Arai M; Iwase T; Takazawa Y; Takeshima N
    Gan To Kagaku Ryoho; 2014 Nov; 41(11):1333-9. PubMed ID: 25434434
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comprehensive mutation detection of BRCA1/2 genes reveals large genomic rearrangements contribute to hereditary breast and ovarian cancer in Chinese women.
    Cao WM; Zheng YB; Gao Y; Ding XW; Sun Y; Huang Y; Lou CJ; Pan ZW; Peng G; Wang XJ
    BMC Cancer; 2019 Jun; 19(1):551. PubMed ID: 31174498
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Characterization of mutations in BRCA1/2 and the relationship with clinic-pathological features of breast cancer in a hereditarily high-risk sample of chinese population.
    Fang M; Zhu L; Li H; Li X; Wu Y; Wu K; Lin J; Sheng Y; Yu Y
    Oncol Lett; 2018 Mar; 15(3):3068-3074. PubMed ID: 29435039
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.